NCT05181254

Brief Summary

In the current project, primary health care patients with mental illness such as anxiety, depression, fatigue or sleep disorders will be followed. The study includes both health conversations with the health curve as a systematic work with lifestyle habits, and the biochemical risk marker copeptin with a focus on improved lifestyle habits and the development of cardiovascular complications. Participants will be followed up at 12 and 24 months with renewed health interview including the health curve and blood sampling. National registries will be used for a, up to 20 year long follow-up regarding cardiovascular complications and mortality.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
167

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2020

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

October 31, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

January 6, 2022

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 24, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 24, 2025

Completed
Last Updated

May 1, 2026

Status Verified

November 1, 2025

Enrollment Period

5.9 years

First QC Date

October 31, 2021

Last Update Submit

April 27, 2026

Conditions

Keywords

primary health carehealth dialoguelong-term follow-upmental illness

Outcome Measures

Primary Outcomes (1)

  • Proportion of patients who change their risk profile

    Proportion of patients who achieve a change in the risk profile on the Health Dialogue. A positive change ("yes") is defined if a larger number of the variables on the Health Curve have improved than deteriorated. "No" is defined as no change or negative change has taken place.

    24 months from baseline

Secondary Outcomes (22)

  • Self reported risk change

    At 12 and 24 months from baseline

  • Proportion of smokers and number of cigarettes per day

    At baseline and follow-up at 12 and 24 months from baseline.

  • Referral to smoking cessation

    At 12 and 24 months from baseline

  • Time and intensity in physical activity

    At baseline and follow-up at 12 and 24 months from baseline.

  • Referral PaR-S

    At 12 and 24 months from baseline

  • +17 more secondary outcomes

Study Arms (1)

Health dialogue

EXPERIMENTAL

Patients \> 18 years old seeking primary care for mental illness (depression, anxiety, sleep disorders or stress related problems) will be followed at 12 and 24 months from baseline in a first assessment, and after 5 and 10 years with follow-up in national registers in a later phase. The patient will fill out a web-based questionnaire about lifestyle habits before the visit to the health center and will be called for blood sampling and measurement of blood pressure and BMI. A nurse with special training in the Health Dialogue then meets the patient and provides individually tailored advice based on the patient's unique conditions and the risk profile on the Health Dialogue, such as help with smoking cessation, physical activity on prescription (PaR-S), contact with a dietitian, physiotherapist. A continued contact with a psychologist or physician will be planned if necessary

Behavioral: health dialogue

Interventions

health dialogueBEHAVIORAL

The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.

Also known as: The health curve
Health dialogue

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients \> 18 years old seeking primary care for mental illness (depression, anxiety, sleep disorders or stress related problems

You may not qualify if:

  • Dementia, not speaking, writing or understanding spoken the Swedish language.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peter Nymberg

Helsingborg, Region Skane, 253 62, Sweden

Location

Related Publications (24)

  • Gibson M, Carek PJ, Sullivan B. Treatment of co-morbid mental illness in primary care: how to minimize weight gain, diabetes, and metabolic syndrome. Int J Psychiatry Med. 2011;41(2):127-42. doi: 10.2190/PM.41.2.c.

    PMID: 21675345BACKGROUND
  • Jao NC, Robinson LD, Kelly PJ, Ciecierski CC, Hitsman B. Unhealthy behavior clustering and mental health status in United States college students. J Am Coll Health. 2019 Nov-Dec;67(8):790-800. doi: 10.1080/07448481.2018.1515744. Epub 2018 Nov 28.

    PMID: 30485154BACKGROUND
  • Wu Q, Kling JM. Depression and the Risk of Myocardial Infarction and Coronary Death: A Meta-Analysis of Prospective Cohort Studies. Medicine (Baltimore). 2016 Feb;95(6):e2815. doi: 10.1097/MD.0000000000002815.

    PMID: 26871852BACKGROUND
  • Bonow RO. Primary prevention of cardiovascular disease: a call to action. Circulation. 2002 Dec 17;106(25):3140-1. doi: 10.1161/01.cir.0000048067.86569.e1. No abstract available.

    PMID: 12485965BACKGROUND
  • Stumbo SP, Yarborough BJH, Yarborough MT, Green CA. Perspectives on Providing And Receiving Preventive Health Care From Primary Care Providers and Their Patients With Mental Illnesses. Am J Health Promot. 2018 Nov;32(8):1730-1739. doi: 10.1177/0890117118763233. Epub 2018 Apr 15.

    PMID: 29658287BACKGROUND
  • Neeleman J, Oldehinkel AJ, Ormel J. Positive life change and remission of non-psychotic mental illness. A competing outcomes approach. J Affect Disord. 2003 Sep;76(1-3):69-78. doi: 10.1016/s0165-0327(02)00068-x.

    PMID: 12943935BACKGROUND
  • Ronngren Y, Bjork A, Kristiansen L, Haage D, Enmarker I, Audulv A. Meeting the needs? Perceived support of a nurse-led lifestyle programme for young adults with mental illness in a primary health-care setting. Int J Ment Health Nurs. 2018 Feb;27(1):390-399. doi: 10.1111/inm.12333. Epub 2017 Apr 4.

    PMID: 28374967BACKGROUND
  • Forsyth A, Deane FP, Williams P. A lifestyle intervention for primary care patients with depression and anxiety: A randomised controlled trial. Psychiatry Res. 2015 Dec 15;230(2):537-44. doi: 10.1016/j.psychres.2015.10.001. Epub 2015 Oct 3.

    PMID: 26453120BACKGROUND
  • Lingfors H, Persson LG, Lindstrom K, Bengtsson C, Lissner L. Effects of a global health and risk assessment tool for prevention of ischemic heart disease in an individual health dialogue compared with a community health strategy only results from the Live for Life health promotion programme. Prev Med. 2009 Jan;48(1):20-4. doi: 10.1016/j.ypmed.2008.10.009. Epub 2008 Nov 1.

    PMID: 19013188BACKGROUND
  • Farnkvist L, Olofsson N, Weinehall L. Did a health dialogue matter? Self-reported cardiovascular disease and diabetes 11 years after health screening. Scand J Prim Health Care. 2008;26(3):135-9. doi: 10.1080/02813430802113029.

    PMID: 18609252BACKGROUND
  • Persson LG, Lindstrom K, Lingfors H, Bengtsson C, Lissner L. Cardiovascular risk during early adult life. Risk markers among participants in "Live for Life" health promotion programme in Sweden. J Epidemiol Community Health. 1998 Jul;52(7):425-32. doi: 10.1136/jech.52.7.425.

    PMID: 9799876BACKGROUND
  • Lingfors H, Lindstrom K, Persson LG, Bengtsson C, Lissner L. Lifestyle changes after a health dialogue. Results from the Live for Life health promotion programme. Scand J Prim Health Care. 2003 Dec;21(4):248-52. doi: 10.1080/02813430310003282.

    PMID: 14695077BACKGROUND
  • Persson LG, Lingfors H, Nilsson M, Molstad S. The possibility of lifestyle and biological risk markers to predict morbidity and mortality in a cohort of young men after 26 years follow-up. BMJ Open. 2015 May 6;5(5):e006798. doi: 10.1136/bmjopen-2014-006798.

    PMID: 25948404BACKGROUND
  • Lingfors H, Persson LG. All-cause mortality among young men 24-26 years after a lifestyle health dialogue in a Swedish primary care setting: a longitudinal follow-up register study. BMJ Open. 2019 Jan 29;9(1):e022474. doi: 10.1136/bmjopen-2018-022474.

    PMID: 30696668BACKGROUND
  • Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010 May 18;121(19):2102-8. doi: 10.1161/CIRCULATIONAHA.109.909663. Epub 2010 May 3.

    PMID: 20439785BACKGROUND
  • Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016 Jan;102(2):127-32. doi: 10.1136/heartjnl-2015-308183. Epub 2015 Dec 9.

    PMID: 26661323BACKGROUND
  • Enhorning S, Christensson A, Melander O. Plasma copeptin as a predictor of kidney disease. Nephrol Dial Transplant. 2019 Jan 1;34(1):74-82. doi: 10.1093/ndt/gfy017.

    PMID: 29471407BACKGROUND
  • Pikkemaat M, Melander O, Bengtsson Bostrom K. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complications. 2015 Nov-Dec;29(8):1062-5. doi: 10.1016/j.jdiacomp.2015.07.006. Epub 2015 Jul 9.

    PMID: 26321369BACKGROUND
  • Krogh J, Gotze JP, Jorgensen MB, Kristensen LO, Kistorp C, Nordentoft M. Copeptin during rest and exercise in major depression. J Affect Disord. 2013 Oct;151(1):284-90. doi: 10.1016/j.jad.2013.06.007. Epub 2013 Jul 13.

    PMID: 23856279BACKGROUND
  • Siegenthaler J, Walti C, Urwyler SA, Schuetz P, Christ-Crain M. Copeptin concentrations during psychological stress: the PsyCo study. Eur J Endocrinol. 2014 Dec;171(6):737-42. doi: 10.1530/EJE-14-0405. Epub 2014 Sep 23.

    PMID: 25249697BACKGROUND
  • Kaczmarczyk M, Spitzer C, Wingenfeld K, Wiedemann K, Kuehl LK, Schultebraucks K, Deuter CE, Otte C. No association between major depression with and without childhood adversity and the stress hormone copeptin. Eur J Psychotraumatol. 2020 Nov 2;11(1):1837511. doi: 10.1080/20008198.2020.1837511.

    PMID: 33244366BACKGROUND
  • Agorastos A, Sommer A, Heinig A, Wiedemann K, Demiralay C. Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study. Front Psychiatry. 2020 May 20;11:453. doi: 10.3389/fpsyt.2020.00453. eCollection 2020.

    PMID: 32508691BACKGROUND
  • Milos Nymberg V, Pikkemaat M, Calling S, Nymberg P. HEAD-MIP-(HEAlth Dialogues for patients with Mental Illness in Primary care)-a feasibility study. Pilot Feasibility Stud. 2023 Sep 28;9(1):167. doi: 10.1186/s40814-023-01391-2.

  • Pikkemaat M, Nymberg VM, Nymberg P. Structured assessment of modifiable lifestyle habits among patients with mental illnesses in primary care. Sci Rep. 2022 Jul 19;12(1):12292. doi: 10.1038/s41598-022-16439-1.

MeSH Terms

Conditions

Mental DisordersFatigueSleep Wake DisordersDepressionDiabetes MellitusCardiomyopathiesStrokeDeath

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsNervous System DiseasesNeurologic ManifestationsBehavioral SymptomsBehaviorGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesHeart DiseasesCardiovascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesVascular DiseasesPathologic Processes

Study Officials

  • Miriam Pikkemaat, PhD

    Lund University/ Region Skane

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 31, 2021

First Posted

January 6, 2022

Study Start

January 1, 2020

Primary Completion

November 24, 2025

Study Completion

November 24, 2025

Last Updated

May 1, 2026

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations